# The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

> **NCT00566735** · PHASE3 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 39 (actual)

## Conditions studied

- Major Depression
- Bipolar Depression
- Schizoaffective Disorder

## Interventions

- **DRUG:** Razadyne
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00566735
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2012-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00566735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00566735, "The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00566735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*